These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32649714)

  • 1. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
    van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
    PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Switching from acenocoumarol to phenprocoumon: step in personalised anticoagulation?].
    van Miert JHA; Piersma-Wichers M; Meijer K
    Ned Tijdschr Geneeskd; 2021 Sep; 165():. PubMed ID: 34523845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
    Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
    van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
    Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
    Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
    J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon.
    Gadisseur AP; van der Meer FJ; Adriaansen HJ; Fihn SD; Rosendaal FR
    Br J Haematol; 2002 Jun; 117(4):940-6. PubMed ID: 12060134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry.
    Le Heuzey JY; Ammentorp B; Darius H; De Caterina R; Schilling RJ; Schmitt J; Zamorano JL; Kirchhof P
    Thromb Haemost; 2014 May; 111(5):833-41. PubMed ID: 24651882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
    Fihn SD; Gadisseur AA; Pasterkamp E; van der Meer FJ; Breukink-Engbers WG; Geven-Boere LM; van Meegen E; de Vries-Goldschmeding H; Antheunissen-Anneveld I; van't Hoff AR; Harderman D; Smink M; Rosendaal FR
    Thromb Haemost; 2003 Aug; 90(2):260-6. PubMed ID: 12888873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
    Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
    Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
    J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin use decreases coagulation in users of vitamin K antagonists.
    van Rein N; Biedermann JS; Bonafacio SM; Kruip MJ; van der Meer FJ; Lijfering WM
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1441-1447. PubMed ID: 27709253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists.
    Demelo-Rodríguez P; Postigo-Esteban A; García-Fernández-Bravo I; Agud M; Calpena S; Camacho M; Del Toro-Cervera J
    Thromb Res; 2016 Nov; 147():58-60. PubMed ID: 27676254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation.
    van den Besselaar AM; Biedermann JS; van der Meer FJ; Adriaansen HJ; Leebeek FW; Kruip MJ
    Thromb Haemost; 2016 Sep; 116(4):679-86. PubMed ID: 27384264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist.
    van den Besselaar AM; Biedermann JS; Kruip MJ
    Thromb Haemost; 2015 Nov; 114(6):1260-7. PubMed ID: 26202616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; Haas FJ; Levi M; Sturk A
    Thromb Haemost; 2007 Oct; 98(4):738-46. PubMed ID: 17938796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL.
    Prochaska JH; Göbel S; Keller K; Coldewey M; Ullmann A; Lamparter H; Jünger C; Al-Bayati Z; Baer C; Walter U; Bickel C; ten Cate H; Münzel T; Wild PS
    BMC Med; 2015 Jan; 13():14. PubMed ID: 25616558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenprocoumon and acenocoumarol treatment in paediatric patients.
    Spoor N; Smiers FJ; van der Meer FJ; Hutten BA; van Ommen CH
    Thromb Haemost; 2012 Dec; 108(6):1238-41. PubMed ID: 23014894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.